June 21, 2018
trial_results

Pediatric Oncology – Key Results from ASCO 2018

Pembrolizumab demonstrated durable anti-tumor activity in various tumors specially Hodgkin Lymphoma (ORR: 50%, mPFS: 12.2 months, 12 month PFS rate: 59.7%). The results indicate further study of pembrolizumab in pediatric patients with particulate interest in Lymphoma Phase 2 Study results confirms PR rate of 72% with that of phase 1 […]
June 5, 2018
financial_incentive

Strategies to Accelerate Innovation in Pediatric Space

  Why is it so difficult to develop drugs for children with cancer? What can be done to stimlate investments in the pediatric oncology space?  These questions are central to a new study published by MIT Sloan researchers that explores new business models for funding drug development to treat pediatric cancers.  The […]
June 2, 2018
milestone

Major Milestones In Cancer Research

Research and development within the cancer field is continuously evolving and progressing. This video highlights the biggest milestones within the field of cancer research spanning 170 years —from the advent of general anesthesia opening the door for cancer surgery in the mid-1800s to the first gene therapy for cancer approved by the […]
June 2, 2018
Lymphoma - ASCO18

Top ASCO 2018 Abstracts To Watch Out For In Lymphoma

Abstract 7504: Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 (5F9) with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. Conclusion: 5F9 + rituximab is a novel immunotherapy that inhibits a key macrophage/cancer checkpoint. It is well tolerated with no MTD reached and has promising clinical activity […]
June 2, 2018
Genitourinary cancer - ASCO18

Top ASCO 2018 Abstracts To Watch Out For In Genitourinary Cancers

Abstract 5003: Olaparib (Lynparza) combined with abiraterone (Zytiga) in patients with metastatic castration-resistant prostate cancer (mCRPC): a randomized phase II trial Conclusion: This is the first trial to show clinical benefit (increase in PFS) for mCRPC pts treated with a PARP inhibitor combined with abiraterone, regardless of HRRm status. Safety […]
June 2, 2018
Gastrointestinal cancer - ASCO18

Top ASCO 2018 Abstracts To Watch Out For In Gastrointestinal Cancers

Abstract 4011: A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal junction cancer refractory to trastuzumab (Herceptin) combined with fluoropyrimidine and platinum: WJOG7112G. Conclusion: Continuation of trastuzumab beyond progression (TMB Strategy) in this patient population was not found to have the […]